Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Revenue (2019 - 2023)

Historic Revenue for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $14.5 million.

  • ADC Therapeutics' Revenue fell 8101.05% to $14.5 million in Q3 2023 from the same period last year, while for Dec 2023 it was $52.8 million, marking a year-over-year decrease of 9992.46%. This contributed to the annual value of $209908.0 for FY2022, which is 51888.73% up from last year.
  • As of Q3 2023, ADC Therapeutics' Revenue stood at $14.5 million, which was down 8101.05% from $19.3 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Revenue peaked at $69.8 billion during Q4 2022, and registered a low of $13.15 during Q3 2021.
  • In the last 5 years, ADC Therapeutics' Revenue had a median value of $9.1 million in 2021 and averaged $5.0 billion.
  • As far as peak fluctuations go, ADC Therapeutics' Revenue crashed by 9093.31% in 2021, and later surged by 58052017078.42% in 2022.
  • Quarter analysis of 5 years shows ADC Therapeutics' Revenue stood at $222.0 in 2019, then tumbled by 34.68% to $145.0 in 2020, then tumbled by 90.93% to $13.15 in 2021, then skyrocketed by 530904388733.95% to $69.8 billion in 2022, then crashed by 99.98% to $14.5 million in 2023.
  • Its Revenue was $14.5 million in Q3 2023, compared to $19.3 million in Q2 2023 and $19.0 million in Q1 2023.